ABX-1431
Behavioral treatment of tics from home
ABX-1431 is a new preparation developed by the company Abide Therapeutics. From a pharmacological point of view, it represents a novel treatment approach. The drug inhibits the breakdown of the body's own messenger substances, known as endocannabinoids, which bind to the cannabinoid receptors in the brain. There are indications that the effect of ABX-1431 is comparable to cannabis-based drugs. However, ABX-1431 appears to be more effective and better tolerated compared to cannabis-based drugs.
Based on clinical experience with the use of cannabis-based drugs for the treatment of Tourette's syndrome, ABX-1431 is expected to improve not only the tics but also the accompanying psychiatric disorders.
The investigational drug ABX-1431 proved to be well tolerated in the first human studies. It is now to be tested in a 10-week study in adults with Tourette's syndrome.
This study is currently completed.
Study results are not yet available.
If you are generally interested in the study, you can contact us at the following e-mail address: tourette-studien@mh-hannover.de
Contact if you wish to participate
☎ 0511-532-5524
Email: psy-abx-1431@mh-hannover.de
back